CORRECTION article
Front. Immunol.
Sec. Viral Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1594972
Corrigendum: Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions
Provisionally accepted- 1Translational Health Science and Technology Institute (THSTI), Faridabad, India
- 2Central Drug Research Institute (CSIR), Lucknow, Uttar Pradesh, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
PAGE \* Arabic \* MERGEFORMAT 3In the published article, there was an error in [Figure 5D (FACS panel of Th0 & Th2)] as published. [The FACS images in Figure 5D (Th0 & Th2 panel) were originally generated by Upasna Madan, a graduate student, as part of a broader project investigating the in vitro immunomodulatory effects of eight herbal extracts. Initially, all experiments were conducted with multiple biological and technical replicates, intending to publish the findings in a single manuscript. However, during analysis, we determined that presenting the data in multiple manuscripts, each focusing on a specific herbal extract, would be more effective.During this segmentation process, representative control images from the FACS analysis were inadvertently reused in two different manuscripts (PMID: 36960064 & PMID: 37765142). Since each experiment included multiple control replicates, we are in the process of replacing the affected control FACS plots. Importantly, as these FACS plots pertain only to control conditions, their replacement does not alter the overall findings, interpretations, or conclusions of either manuscript].The corrected [Figure 5D, Th0 & Th2 panel] and its caption
Keywords: Withania somnifera (Ashwagandha), Tinospora cordifolia, SARS-CoV-2, hamster model, T cells, Neutrophils, and hACE2 transgenic mice, COVID-19
Received: 17 Mar 2025; Accepted: 11 Apr 2025.
Copyright: © 2025 Rizvi, Madan, Sadhu, Tripathy, Goswami, Mani, Dikshit and Awasthi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zaigham Abbas Rizvi, Translational Health Science and Technology Institute (THSTI), Faridabad, India
Madhu Dikshit, Central Drug Research Institute (CSIR), Lucknow, 226031, Uttar Pradesh, India
Amit Awasthi, Translational Health Science and Technology Institute (THSTI), Faridabad, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.